We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Drug Boosts Potency of Chemotherapy

By Biotechdaily staff writers
Posted on 29 Dec 2004
Cancer researchers have found that a recently discovered nontoxic imidazoline compound, SP-4-84, significantly increases the potency of anticancer drugs such as cisplatin and camptothecin.

Investigators at Michigan State University (East Lansing, USA) worked with normal and cancer cells growing in tissue culture. More...
They reported in the December 2004 issue of Chemistry & Biology that the novel imidazoline compound SP-4-84 increased the sensitivity of the cancer cells to the chemotherapeutic drug camptothecin by about 75% without having a toxic effect on normal cells.

The mode of activity of SP-4-84 is through inhibition of NF-kappa-B-mediated gene transcription, which is known to sensitize tumor cells to chemotherapeutic agents and enhance their efficacy.

Senior author Dr. Jetze Tepe, assistant professor of chemistry at Michigan State University said, "Essentially it sensitizes only cancer cells to chemotherapeutics by blocking the cancer cell's ability to survive the damage that was caused by the chemotherapeutic drugs. This may potentially mean that one could use less than one-tenth of the current drug dosage and still get the same therapeutic results, but fewer side effects, or use the same drug dosage which is now much more effective in its treatment.”




Related Links:
Michigan State University

New
Gold Member
Aspiration System
VACUSAFE
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
POC Immunoassay Analyzer
Procise DX
New
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.